N-(2,6-dichlorophenyl)-4,5-di(propan-2-yl)-4,5-dihydro-1H-imidazol-2-amine;hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2,6-dichlorophenyl)-4,5-di(propan-2-yl)-4,5-dihydro-1H-imidazol-2-amine;hydrochloride
• 化学式: C15H22Cl3N3
• 分子量: 350.7
• InChiKey: HSMHWAGYMUFUCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.84
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  36.4
• 氢给体数：
  3
• 氢受体数：
  1

文献信息

• Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic
  申请人：——

  公开号：US20030187045A1

  公开（公告）日：2003-10-02

  The invention relates to novel compounds of the type of the imidazolidines of the formula I 1 in which R1 to R7 are as defined herein. In one embodiment, these compounds are used for the treatment of the central nervous system, of lipid metabolism, of infection by ectoparasites, of disorders of gall function and for improving the respiratory drive such as for treating respiratory distress. In another embodiment, the compounds increase the muscle tone of the upper respiratory tract, thus suppressing snoring.

  这项发明涉及公式I中咪唑啉类新化合物，其中R1至R7如本文所定义。在一个实施例中，这些化合物用于治疗中枢神经系统、脂质代谢、外寄生虫感染、胆囊功能紊乱以及改善呼吸驱动，例如用于治疗呼吸窘迫。在另一个实施例中，这些化合物增加上呼吸道的肌肉张力，从而抑制打鼾。
• Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic, and medicament comprising them
  申请人：Heinelt Uwe

  公开号：US20050004198A1

  公开（公告）日：2005-01-06

  The invention relates to novel compounds of the type of the imidazolidines of the formula I in which R1 to R7 are as defined in the claims. They are used for preparing a medicament for the treatment or prophylaxis of the central nervous system, of lipid metabolism, of infection by ectoparasites, of disorders of gall function and for improving the respiratory drive and are therefore used for treating respiratory distress. Additionally, the compounds increase the muscle tone of the upper respiratory tract, thus suppressing snoring.

  本发明涉及公式I的咪唑啉类新化合物，其中R1至R7如权利要求所定义。它们用于制备治疗或预防中枢神经系统、脂质代谢、外寄生虫感染、胆囊功能障碍以及改善呼吸驱动力的药物，因此用于治疗呼吸窘迫。此外，这些化合物增加上呼吸道肌肉张力，从而抑制打鼾。
• SUBSTITUIERTE IMIDAZOLIDINE, VERFAHREN ZU IHRER HERSTELLUNG, IHRE VERWENDUNG ALS MEDIKAMENT ODER DIAGNOSTIKUM SOWIE ENTHALTENDES MEDIKAMENT
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1461034B1

  公开（公告）日：2006-11-22
• US7179829B2
  申请人：——

  公开号：US7179829B2

  公开（公告）日：2007-02-20